← boardnext 2026-08next 2026-09next 2026-09-30next 2026-11next 2026-12-01
ARGX
argenxdistress 0/10 · well-funded / low risk$878.23+3%today-7% from 52w high
Neurology 2
Lead: Generalized Myasthenia Gravis · target FcRn
Revenue
$4153M
Liquidity
$4491M
Runway
—
Shares 1y
0%
Price & events
+6.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.1%
1D
+2.4%
1W
+2.9%
1M
+11.5%
3M
+7.8%
6M
+52.6%
1Y
+85.7%
2Y
+177.8%
5Y
+195.7%
All
Overview
- Market Cap
- $54.35B
- Volume
- 78.28K
- 52 Week Range
- $556 – $940
- Total Shares
- 61.88M
- Float Shares
- 1.55B
- Short %
- 2.33%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 47.63%
- RVOL
- 0.23x
- Beta
- -0.02
Pipeline stages · 5 programs
Efgartigimod PH20 (ARGX-113) SC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Empasiprubart, IVIG (Intravenous Immunoglobulin)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Efgartigimod IV or Efgartigimod PH20 SC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Empasiprubart IV
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
EFG PH20 SC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 29 trials · 25 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 final ~2027-02-28 | Phase 2 | ARGX-119 | Amyotrophic Lateral Sclerosis | 60 | active not recruiting |
| 2026-09 Estimated 50% readout ~2026-11-15 | Phase 3 | Empasiprubart, IVIG (Intravenous Immunoglobulin) | Multifocal Motor Neuropathy (MMN), MMN | — | active not recruiting |
| 2026-09-30 Estimated 50% readout ~2026-12-14 | Phase 2/3 | Efgartigimod PH20 SC | Generalized Myasthenia Gravis | — | recruiting |
| 2026-10-01 Estimated 50% readout ~2026-12-15 | Phase 3 | efgartigimod PH20 SC | Primary Immune Thrombocytopenia | — | active not recruiting |
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | Empasiprubart IV | Dermatomyositis, Myositis | — | active not recruiting |
Show all 29 trials · 24 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-01 Estimated 50% readout ~2027-02-14 | Phase 2/3 | EFG PH20 SC | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | — | active not recruiting |
| 2027-02 Estimated 50% readout ~2027-03-18 | Phase 2 | Efgartigimod PH20 SC | Systemic Sclerosis (SSc) | — | recruiting |
| 2027-03 Estimated 50% readout ~2027-05-15 | Phase 2/3 | Efgartigimod IV | Generalized Myasthenia Gravis | — | recruiting |
| 2027-04-30 Estimated 50% readout ~2027-06-14 | Phase 2 | Efgartigimod PH20 SC | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | — | active not recruiting |
| 2027-07 Estimated 50% readout ~2027-09-14 | Phase 3 | Efgartigimod PH20 SC | Primary Sjogrens Disease | — | active not recruiting |
| 2027-09 Estimated 50% readout ~2027-11-15 | Phase 3 | empasiprubart, IVIg | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | — | recruiting |
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | Empasiprubart IV | AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG | — | not yet recruiting |
| 2027-10-07 Estimated 50% readout ~2027-12-21 | Phase 3 | Empasiprubart IV | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy | — | recruiting |
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 2 | Efgartigimod PH20 SC - prefilled syringe | Antibody-mediated Rejection | — | active not recruiting |
| 2028-03-07 Estimated 50% readout ~2028-04-21 | Phase 2 | Efgartigimod IV, Empasiprubart IV | AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG) | — | recruiting |
| 2028-04 Estimated 50% readout ~2028-06-15 | Phase 2/3 | Empasiprubart IV | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | — | not yet recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | Efgartigimod IV | Primary Immune Thrombocytopenia (ITP) | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | efgartigimod PH20 SC | Graves Disease | — | not yet recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | Efgartigimod PH20 SC | Graves' Disease, Graves Disease | — | not yet recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | Efgartigimod PH20 SC | Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | — | enrolling by invitation |
| 2028-10 Estimated 50% readout ~2028-12-15 | Phase 2/3 | Efgartigimod IV | Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura ( ITP ), Idiopathic Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura (ITP) | — | recruiting |
| 2029-05-28 Estimated 50% readout ~2029-07-12 | Phase 2 | ARGX-119 IV | Spinal Muscular Atrophy (SMA) | — | recruiting |
| 2029-09 Estimated 50% readout ~2029-11-15 | Phase 2/3 | Efgartigimod IV or Efgartigimod PH20 SC | Generalized Myasthenia Gravis, gMG | — | enrolling by invitation |
| 2029-09-30 Estimated 50% readout ~2029-11-14 | Phase 2 | ARGX-117 | Multifocal Motor Neuropathy (MMN) | — | active not recruiting |
| 2030-12-04 Estimated 50% readout ~2031-01-18 | Phase 2 | Efgartigimod PH20 (ARGX-113) SC | Autoimmune Encephalitis (AE) | — | not yet recruiting |
| 2026-03-20 | Phase 1 | ARGX-213 | Healthy Volunteers | 88 | completed |
| 2026-01 | Phase 3 | Efgartigimod PH20 SC | Myasthenia Gravis, Ocular | 141 | active not recruiting |
| 2025-12-15 | Phase 3 | Efgartigimod PH20 SC | Thyroid Eye Disease | 105 | terminated |
| 2025-10-16 | Phase 2 | ARGX-117 | Delayed Graft Function | 103 | active not recruiting |
Catalyst news & presentations · 1
- 2026-07-23Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $1055 (+20% upside) · 23 analysts
- 2026-07-21CitigroupBuy
- 2026-07-07RBC CapitalOutperform
- 2026-07-02B of A SecuritiesBuy
- 2026-06-25HC Wainwright & Co.Buy
- 2026-06-24Morgan StanleyOverweight
- 2026-06-11WedbushOutperform
Recent news
- 2026-07-23ARGX Reports Strong Q2 Revenue Growth Amid Expanded Product Launch - GuruFocus
- 2026-07-23Earnings call transcript: argenx posts strong Q2 2026 growth as VYVGART expands - Investing.com
- 2026-07-23ARGENX : Bernstein gives a Buy rating - marketscreener.com
- 2026-07-23argenx (NASDAQ: ARGX) grows Q2 sales to $1.5B, profit $838M - Stock Titan
- 2026-07-23Argenx SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
- 2026-07-23Argenx soars on strong Vyvgart sales, beating estimates By Investing.com - Investing.com South Africa
- 2026-07-23Argenx: Sales Increase by 60% in Q2, Profit Reaches $838M in H1 - Idéal Investisseur
- 2026-07-23argenx SE reports results for the quarter ended June 30 - Earnings Summary - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.